Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Herantis Pharma Plc – Press release on 28 May 2026 at 2:30 pm EEST
Webcast: Update on Phase 2 preparation
Espoo, Finland, 28 May 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that Herantis’ management team will host a webcast on Tuesday 2 June 2026, at 13.00 EEST (12:00 CEST).
Herantis CEO Antti Vuolanto, CSO Henri Huttunen and CFO Tone Kvåle will provide an overview of recent corporate developments. Topics to be covered include:
- Outline of the Phase 2a proof-of-concept efficacy study
- Collaboration with Indivi to integrate its digital biomarker platform into the upcoming Phase 2a proof-of-concept efficacy study of HER-096
- Q&A session
Questions can be submitted throughout the webcast event.
Attendees are invited to pre-register and join the online event using the following link: https://herantis.videosync.fi/update-on-phase-2-preparation
A recording of the webcast will be available on the Company’s website after the event has concluded.
For more information, please contact:
Herantis Pharma Plc
Antti Vuolanto, CEO
Tel: +358407517329
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
ICR Healthcare
Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage
Tel: +44 20 3709 5700
Email: herantispharma@icrhealthcare.com
Certified Advisor:
UB Corporate Finance Ltd
Tel: +358 9 25 380 225
Email: ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.
Herantis is listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com